# BAT account plan

> BAT is a global tobacco and nicotine group with £25,610m of 2025 revenue, 47,000+ employees and Smokeless brands Vuse, glo and Velo.

## At a glance

BAT (British American Tobacco p.l.c.) is a multi-category tobacco and nicotine group selling combustibles in more than 140 markets alongside Smokeless products: Vapour (Vuse), Heated Products (glo), Modern Oral (Velo) and Traditional Oral (Grizzly, Kodiak, Camel Snus). It sells to retailers, key accounts, distributors and wholesalers and increasingly direct to consumers, and reports three regions: the U.S. (Reynolds American), AME and APMEA. FY2025 revenue was £25,610m, down 1.0% reported but up 2.1% at constant rates, with profit from operations of £9,997m and diluted EPS of 349.1p. It employs 47,000+ people and ran 36 cigarette factories in 35 markets in 2025. Its strategy, "Building a Smokeless World", targets more than 50% of revenue from Smokeless products by 2035.

## Business units

- **U.S. (Reynolds American)** (£11,534m of FY2025 revenue (about 45% of Group, computed)): BAT's top market for cigarettes, Vapour, Modern Oral and Traditional Oral, with brands including Newport, Camel, Natural American Spirit, Vuse, Velo and Grizzly; led by David Waterfield, President and CEO, Reynolds American Inc. Revenue grew 5.5% at constant rates in 2025 and 8.5% in H1 2026, driven by Velo Plus and Vuse.
- **AME (Americas and Europe)** (£9,309m of FY2025 revenue (about 36% of Group, computed)): Top cigarette markets include Brazil, Germany, Mexico and Romania, and BAT leads Modern Oral in Scandinavia; led by Fred Monteiro, Regional Director. Revenue rose 3.3% at constant rates in 2025 and 0.9% in H1 2026, with Vapour hit by illicit products and regulation.
- **APMEA (Asia-Pacific, Middle East and Africa)** (£4,767m of FY2025 revenue (about 19% of Group, computed)): Top markets include Japan and Pakistan for cigarettes and Japan and South Korea for Heated Products. Revenue fell 7.2% at constant rates in 2025 and 6.3% in H1 2026 on illicit trade in Australia and excise in Bangladesh; Pascale Meulemeester became Regional Director from 1 January 2026.

## Strategic priorities

- **Building a Smokeless World**: More than 50% of revenue from Smokeless products by 2035 and 50 million Smokeless consumers by 2030; Smokeless reached 19.8% of Group revenue and 35.0m consumers in H1 2026.
- **Horizon 2030 growth algorithm**: 3-5% revenue, 4-6% adjusted profit and 5-8% adjusted diluted EPS growth, with combustibles at 1-2% and New Categories at mid-teens growth and at least a 30% contribution margin by 2030.
- **Modern Oral as growth driver**: Velo is the global Modern Oral leader; Modern Oral revenue grew 65.9% at constant rates in H1 2026 and BAT expects industry revenue in the category to almost triple by 2030.
- **U.S. as growth cornerstone**: A £42bn revenue pool where BAT built local Velo Plus manufacturing and over 90% weighted distribution within 18 months; Velo Max and adult-focused Vuse flavours launch in H2 2026.
- **Productivity and Fit2Win**: £2bn of productivity savings targeted for 2026-2030 plus c.£700m of annualised Fit2Win efficiencies by end-2028, after £1.2bn saved over 2023-2025.
- **Combustibles focus and cash generation**: Concentrate on 20 key markets with 80% of industry revenue, and generate more than £50bn of free cash flow before dividends over 2024-2030.

## Latest results

In the six months to 30 June 2026 revenue was £12,235m, up 1.4% reported and 2.9% at constant rates, with the U.S. up 8.5%, AME up 0.9% and APMEA down 6.3%. New Categories revenue rose 18.0% at constant rates to £1,928m and New Category contribution rose 54.7% to £269m at a 13.8% margin. Reported profit from operations fell 15.8% to £4,266m after £370m of Fit2Win costs, while adjusted profit from operations, adjusted for Canada, rose 3.5%. For FY2026 BAT guides to revenue and adjusted profit growth at the lower end of the 3-5% and 4-6% ranges, mid-teens New Category revenue growth and leverage within 2.0-2.5x by year end.

## Investments and deals

- **Capital expenditure**: Gross capital expenditure of £648m in 2025, including Modern Oral capacity, and about £750m expected in 2026.
- **Fit2Win programme**: A 2025-2027 programme to raise commerciality and agility, with one-off costs now about £950m; £482m incurred and c.£105m of savings realised by H1 2026.
- **Portfolio moves**: Partial monetisation of ITC (net proceeds £1,052m), sale of the 50% Brascuba (Cuba) stake in February 2026, and exits from Vapour in several APMEA markets.
- **Beyond Nicotine and ventures**: Btomorrow Ventures has made 30+ investments with a £350m commitment, and BAT holds 48.7% of Organigram after its Sanity Group deal, with voting capped at 30%.
- **AI and data foundation**: Around 1,000 AI agents in daily use, AI access for every employee with a computer, and Global Shared Services transitioned to Accenture in July 2025.

## Challenges and risks

- **Illicit trade**: Illicit trade is above 15% of global tobacco volume and an estimated 70% of the U.S. vapour market; in Australia illicit is around 80% of combustibles industry volume.
- **Regulation and excise shocks**: Generational sales bans, flavour bans, excise increases in Bangladesh and a massive excise shock in Brazil from 1 August 2026, which cut BAT's industry volume assumption to -3%.
- **Heated Products losses**: Heated Products revenue fell 11.7% at constant rates in H1 2026; BAT calls the category highly contested, with 2026 the peak investment year.
- **Leverage and finance costs**: Borrowings of £35,063m at H1 2026 and leverage of 2.55x adjusted for Canada at end-2025, above the 2.0-2.5x target.
- **Combustibles volume decline**: Cigarette volume fell 4.6% to 218 billion sticks in H1 2026, and U.S. consumers downtrade to deep discount, where BAT is investing behind Doral.

## What leadership says

> "We said 2025 would be a deployment year – and we have delivered." — Tadeu Marroco, Chief Executive, Combined Annual and Sustainability Report 2025, February 2026

> "After a period of investment and transition, returning to our algorithm for the full year is an important milestone." — Tadeu Marroco, Chief Executive, 2026 interim results webcast, 30 July 2026

> "Two years ago, it was our biggest question mark; today it is our proof point." — Tadeu Marroco, Chief Executive, Capital Markets Day, Winston-Salem, 29 September 2026, on the U.S.

> "We are on track to deliver our growth algorithm, supported by quality revenue growth, improving profitability, strong cash generation and disciplined capital allocation." — Johan Vandermeulen, Chief Operating Officer, Capital Markets Day, 29 September 2026


## Where a supplier can help

- **Productivity and cost programmes**: The £2bn 2026-2030 productivity target and Fit2Win route-to-market modernisation create demand for automation, procurement and operations efficiency partners.
- **Modern Oral capacity and supply**: Modern Oral growth and the capex plan of about £750m in 2026 point to needs in pouch manufacturing capacity, packaging and supply chain.
- **Retail execution and age verification**: U.S. Vuse flavour roll-outs to 25,000 outlets per quarter with ID-scan commitments, and enforcement against illicit vapour, favour retail technology, compliance and track-and-trace suppliers.
- **Data and AI capabilities**: BAT's next-generation data foundation built through partnerships and around 1,000 AI agents in daily use open room for data, AI and analytics vendors.
- **Direct-to-consumer and B2B commerce**: The growing Direct-to-Consumer e-commerce channel and digital B2B platforms for retailers support e-commerce and trade marketing tools.

_Tamtam's reading of the priorities and challenges above, not the company's own words._

## Key documents

### [Combined Annual and Sustainability Report 2025](https://www.bat.com/content/dam/batcom/global/main-nav/investors-and-reporting/reporting/combined-annual-and-sustainability-report/BAT_Annual_Report_2025.pdf)

Annual report · 2026-02-13

- BAT (British American Tobacco p.l.c.) is a global tobacco and nicotine group selling combustibles in >140 markets plus Smokeless products (Vapour: Vuse; Heated Products: glo; Modern Oral: Velo; Traditional Oral: Grizzly, Kodiak, Camel Snus); 47,000+ employees, 36 cigarette factories in 35 markets.
- FY2025 revenue £25,610m, down 1.0% reported (3.1% translational FX headwind) but up 2.1% at constant rates; by region U.S. £11,534m, AME £9,309m, APMEA £4,767m.
- Profit from operations £9,997m (2024: £2,736m, hit by a £6.2bn Canadian settlement charge); adjusted profit from operations, adjusted for Canada, up 2.3% at constant rates to £11,628m; diluted EPS 349.1p; dividend up 2.0% to 245.04p.
- New Categories revenue £3,621m (+7.0% at constant rates), with Modern Oral up 47.4% to £1,165m on the U.S. roll-out of Velo Plus, HP £914m and Vapour down 10.4% to £1,542m on illicit single-use vapes; New Category contribution margin rose 4.7 ppts to 12.0%; Smokeless reached 18.2% of Group revenue and 34.1 million consumers.
- Strategy "Building a Smokeless World": >50% of revenue from Smokeless products by 2035, 50 million Smokeless consumers by 2030; medium-term algorithm of 3-5% revenue and 5-8% adjusted diluted EPS growth (constant currency, adjusted for Canada) from 2026.
- Efficiency: £1.2bn savings delivered over 2023-2025, a further £2bn targeted 2026-2030, plus the Fit2Win programme (c.£600m annualised efficiencies by end-2028); Global Shared Services transitioned to Accenture in July 2025.
- Capital allocation: leverage 2.55x adjusted for Canada (target 2.0-2.5x), borrowings £35,070m, >£50bn free cash flow before dividends targeted 2024-2030, £1.3bn share buy-back for 2026, gross capex c.£750m in 2026.
- Main risks: illicit trade (above 15% of global tobacco volume; an estimated 70% of the U.S. vapour market), regulation (menthol, nicotine limits, generational sales bans), excise shocks (Bangladesh, Australia), litigation, FX and cyber.
- Leadership: Chair Luc Jobin, CEO Tadeu Marroco, Interim CFO Javed Iqbal (after Soraya Benchikh stepped down in August 2025); CEO: "In 2025, our transformation accelerated, with delivery at the top end of our guidance."

### [Half-Year Report for the six months to 30 June 2026](https://www.bat.com/content/dam/batcom/global/main-nav/investors-and-reporting/results-centre/pdf/HY_2026_Annoucement.pdf)

Interim report · 2026-07-30

- H1 2026 revenue £12,235m, up 1.4% reported and 2.9% at constant rates: U.S. +8.5%, AME +0.9%, APMEA -6.3% (slower than expected recovery).
- Smokeless products reached 19.8% of Group revenue (+1.6 ppts vs FY25) and 35.0m consumers; New Categories revenue £1,928m, +18.0% at constant rates, with Modern Oral +65.9% and Vapour back to growth (+5.3%), HP -11.7%.
- New Category contribution up 54.7% to £269m; contribution margin 13.8% (+3.3 ppts).
- Reported profit from operations down 15.8% to £4,266m (margin 34.9%), after £370m of Fit2Win costs and a smaller Canadian provision credit; adjusted profit from operations, adjusted for Canada, +3.5% with margin 43.7%.
- Reported diluted EPS 145.3p (-28.6%); adjusted diluted EPS adjusted for Canada +7.9% at constant rates to 167.8p; FY26 EPS growth now expected towards the middle of the 5-8% range.
- FY26 guidance: revenue and adjusted profit at the lower end of 3-5% and 4-6%, mid-teens New Category revenue growth, global cigarette industry volume c.-3%, net finance costs c.£1.65bn, leverage within 2.0-2.5x by year end, £1.3bn buy-back.
- U.S.: Velo Plus drove Modern Oral revenue +220% at constant rates (volume share 29.8%); Vuse value share 55.9%; Velo Max and a select range of adult-focused Vuse flavours to roll out in H2 2026.
- Fit2Win savings target raised to c.£700m annualised by end-2028 (one-off costs c.£950m); Dragos Constantinescu to join as CFO from 1 September 2026; Cuba business sold in February 2026.

### [2026 Interim Results Presentation Webcast Transcript](https://www.bat.com/content/dam/batcom/global/main-nav/investors-and-reporting/results-centre/pdf/HY_2026_Transcript.pdf)

Executive talk · Tadeu Marroco, Chief Executive · 2026-07-30

- Transcript of BAT's 30 July 2026 interim results webcast with CEO Tadeu Marroco and Interim CFO Javed Iqbal, plus analyst Q&A.
- Marroco: Smokeless is 19.8% of revenue and 35 million consumers; returning to the 5-8% EPS algorithm for the full year is "an important milestone".
- U.S. is the core: BAT calls itself "the fastest growing company in total nicotine"; Velo takes around 90% of Modern Oral value growth, Vuse a record 55.9% value share; Velo Max and adult-focused Vuse flavours (first 25,000 outlets in Q3, another 25,000 in Q4) launch in H2.
- U.S. combustibles grew 5% in H1, of which close to 2 points were trade inventory moves that unwind in H2; BAT will invest in its portfolio and the growing low-price segment, including Doral.
- Modern Oral: 7.9 billion pouches shipped in H1, 39% volume share in top markets, 63% in AME, 32 markets with category regulation.
- Heated Products being "reset" with glo Hilo (nine markets, around 70% of industry volume) and Hyper Pro Plus; Vapour exits in Asia, Poland and UK compliance concerns.
- Iqbal: Fit2Win now £700m annualised savings by 2028 (£500m by 2027), one-off costs £950m; net finance costs c.£1.65bn; EPS growth around 4-4.5% on a current-currency basis.
- The cigarette industry volume assumption was cut to -3%, driven by an excise shock in Brazil from 1 August.

### [Capital Markets Day 2026: Horizon 2030 (CEO prepared remarks)](https://www.bat.com/content/dam/batcom/global/main-nav/investors-and-reporting/investor-presentations/2026-cmd/transcripts/2_Horizon_2030-Transcript-Tadeu_Marroco.pdf)

Executive talk · Tadeu Marroco, Chief Executive · 2026-09-29

- Prepared remarks of CEO Tadeu Marroco opening BAT's Capital Markets Day in Winston-Salem on 29 September 2026: "Horizon 2030".
- Five messages: the momentum is real (New Category revenue +18% in H1, U.S. revenue +8.5%), a long runway of profitable industry growth, New Categories (above all Modern Oral) are where the industry grows, BAT is "performing and transforming at the same time", and a clear path to the 2030 algorithm.
- Industry revenue in BAT's addressable markets expected to grow at around a 4% CAGR 2025-2030; Modern Oral industry revenue expected to almost triple by 2030.
- 2030 algorithm: 3-5% revenue, 4-6% adjusted profit, 5-8% adjusted diluted EPS; combustibles 1-2%, New Categories mid-teens with at least 30% contribution margin by 2030; >£50bn free cash flow 2024-2030.
- U.S. is "our proof point": a £42bn revenue pool; Velo Plus built local manufacturing and >90% weighted distribution within 18 months; Vuse value share close to 57% year to date.
- Vapour: a base case of 30% of the U.S. illicit value pool (around £7bn) returning to the legal market by 2030, a c.£2bn opportunity; Heated Products made selective (glo Hilo premium, Hyper value) with a focus on reducing losses from 2026.
- Combustibles: focus on 20 key markets with 80% of industry revenue; Beyond Nicotine (wellbeing and stimulation, cannabis) is not in the 2030 algorithm.
- Capabilities: around 1,000 AI agents in daily use, 45 manufacturing sites, £2bn productivity savings 2026-2030 plus £700m Fit2Win by 2028; new CFO Dragos and Celina to lead APMEA.

### [Capital Markets Day 2026: Sustainable Shareholder Returns (COO prepared remarks)](https://www.bat.com/content/dam/batcom/global/main-nav/investors-and-reporting/investor-presentations/2026-cmd/transcripts/14_Sustainable_Shareholder_Returns-Transcript-Johan_Vandermeulen.pdf)

Executive talk · Johan Vandermeulen, Chief Operating Officer · 2026-09-29

- Prepared remarks of Johan Vandermeulen, Chief Operating Officer (30+ years at BAT, Management Board since 2014, COO since 2023), at the 29 September 2026 Capital Markets Day: "Sustainable Shareholder Returns".
- Three phases: targeted investment in 2024, progressive improvement in 2025 (U.S. back to growth, Velo Plus profitable within a year), return to the growth algorithm in 2026.
- Choices: HP refocused on the largest profit pools, less investment in Vapour markets without supportive regulation, exits where long-term growth is not compelling.
- Through 2030: New Categories around mid-teens revenue growth, combustibles 1-2% on average, Group revenue 3-5%; New Category contribution margin of at least 30% by 2030; 2026 is the peak investment year for Heated Products.
- Productivity: £1.2bn saved 2023-2025, a further £2bn expected by 2030; adjusted profit back to the lower end of 4-6% in 2026.
- EPS 5-8%, with 1-2pp of accretion beyond operating profit (buy-backs, finance costs, tax, associates), more than 2pp in 2026.
- Cash: around £8bn of free cash flow annually to 2030 and more than £50bn over 2024-2030; nearly £36bn returned since 2021, gross debt down £5bn since 2021, 27 consecutive years of dividend growth, £3.1bn of shares repurchased since 2024 by year end.
- The long-term incentive plan is tied to the algorithm: relative TSR and EPS growth are 45% of the weighting.

## Questions about BAT

### What does BAT do?

BAT makes and sells cigarettes in more than 140 markets and Smokeless nicotine products such as Vuse vapes, glo heated products and Velo nicotine pouches.

### What was BAT's revenue in 2025?

FY2025 revenue was £25,610m, down 1.0% reported and up 2.1% at constant rates; profit from operations was £9,997m.

### How many employees does BAT have?

BAT employs 47,000+ people of 137 nationalities.

### What is BAT's strategy?

"Building a Smokeless World": more than 50% of revenue from Smokeless products by 2035, led by Modern Oral and the U.S., under a Horizon 2030 algorithm of 3-5% revenue and 5-8% adjusted EPS growth.

### Who leads BAT?

Tadeu Marroco is Chief Executive, Luc Jobin is Chair and Dragos Constantinescu became CFO from 1 September 2026; Johan Vandermeulen is Chief Operating Officer.

_Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)_
